In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer's Development Financing: Risky Therapies Call for Innovative Deals

Executive Summary

Eli Lilly has hedged its bets on its two late-stage Alzheimer's disease candidates. In a deal with TPG-Axon and Quintiles' partnering group NovaQuest, Lilly sheds risk (and potentially reward) in this notoriously difficult therapeutic space. A model for private equity / pharma deals going forward?
Advertisement

Related Content

Sanofi Makes Good On Outsourcing Promise In Deal With Covance
Lilly To Cease Development Of Alzheimer's Drug
Lilly Tries to Buy Time
New Frontiers in Pharma R&D Investment
Biopharma in 2008: What a Difference an Economic Crisis Makes
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008
Best of the Blog: IN VIVO, September 2008
Pharma's Strategic Divide: Focus or Diversify
The Alzheimer's Divide
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel